Hexvix guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer

07-Oct-2010 - Norway

Photocure announces a publication in Journal of urology on Hexvix. This publication shows that Hexvix guided fluorescence cystoscopy (Hexvix®), as an adjunct to conventional white-light cystoscopy, improves the detection of bladder cancer and reduces the rate of early tumour recurrence, compared with white-light cystoscopy alone.

The publication is based on Photocure's prospective, randomised study conducted in 28 centres in Europe and North America. The study demonstrated that by using Hexvix®-guided fluorescence cystoscopy Ta/T1 tumours that had not been seen under conventional cystoscopy were detected in 47 (16%) of the patients with Ta or T1 tumours (p=0.001). Of these tumours that were only seen using Hexvix cystoscopy, 28 (59%) were medium-grade tumours (G2), and 19 were tumours of high risk of recurrence and progressions (high grade or T1). Furthermore, 32% of the patients with carcinoma in situ (CIS, a, high-grade aggressive cancer) were identified only by Hexvix®-guided fluorescence cystoscopy.

The study group, led by H. Barton Grossman, Professor of Urology at MD Anderson Cancer Center, Houston, USA, also reports a 16% relative reduction of bladder tumours recurrence in patients with Ta /T1 tumours assessed with Hexvix®-guided fluorescence cystoscopy, compared with white-light cystoscopy alone (p=0.026). At 9 months' follow up, there was a 9% absolute decrease in recurrence in the Hexvix® group, compared with white-light cystoscopy alone, which means that only 11 patients needed to undergo the procedure to avoid one recurrence.

The group also report reduced recurrence of aggressive/clinically significant lesions. They found more CIS, T1 and muscle-invasive disease recurrence in the patients who had undergone white-light cystoscopy compared to Hexvix guided cystoscopy (24% vs 16%, respectively, p=0.17).

As the paper points out, improved tumour detection is likely to result in more accurate tumour mapping and disease staging, and hence more complete cancer resection. A reduced recurrence rate is an objective marker for these benefits.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Genomatix Wins BioChance Grant for $1.6 Mio Research Project into RNAi Mediated Regulatory Networks

Mayo Clinic researchers discover drug can prevent colon cancer development in mice

Merck Announces Elevian as Winner of its North American Advance Biotech Grant - Recombinant protein has the potential to accelerate ischemic and hemorrhagic stroke recovery

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

American Peptide Company Announces Expansion of Its GMP Manufacturing Facility - Company expands capacity to accommodate large scale peptide production for growing customer base

New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel - Capricorn Venture Partners leads 1st financing round of € 3 million

Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Former Becton Dickinson and Wyeth Executive Joins Merck

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

Voyager Therapeutics & Genzyme collaborate to develop and commercialize novel AAV gene therapies for patients with CNS Disorders

Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset

Vertex Pharmaceuticals: Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor

Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea